Navigation Links
Still River Systems Announces Production Milestone for the World's Smallest High-Energy Proton Therapy Accelerator
Date:5/14/2010

LITTLETON, Mass., May 14 /PRNewswire/ -- Still River Systems, Inc. announces successful clinical beam extraction from the first production unit of the world's smallest high-energy proton therapy accelerator. Powerful proton beams are used for the precise treatment of cancer by delivering a highly focused beam of radiation to the tumor while reducing the damage to surrounding healthy tissue and vital organs. This unique accelerator, the world's first superconducting synchrocyclotron, has been specially designed for the Monarch250 Proton Therapy System currently being installed at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO, a National Cancer Institute (NCI) Comprehensive Cancer Center.  

Accelerators have been used in proton therapy for 60 years, but their size, complexity, and cost have limited adoption of this cancer therapy to a few centers around the world.   Still River Systems, based on technology developed at the Massachusetts Institute of Technology's Plasma Science Fusion Center, has now harnessed breakthroughs in superconducting technology to create the world's smallest high-energy proton therapy accelerator.  "The successful testing of our first production accelerator is the culmination of several years of development", explains Dr. Kenneth Gall, Founder and Chief Technology Officer. "We have used advanced superconducting technology and a unique synchrocyclotron design to build a modern accelerator optimized for proton therapy."  With a diameter of only 6 feet and a weight of 20 tons, this accelerator generates a powerful 250 MeV proton beam.

The Siteman Cancer Center will be the first in the world to receive this groundbreaking device.  "As a national leader in cancer treatment, we are excited we will be the first to offer this technology to our patients," says Richard Liekweg, Barnes-Jewish Hospital President. "Many patients choose an NCI designated center like ours because we're able to provide options like proton therapy and this streamlined system will allow us to provide the best treatment possibilities for each patient."

The Robert Wood Johnson University Hospital and the University of Oklahoma Medical Center are two other centers that are currently constructing a proton therapy center to take delivery of Still River Systems revolutionary proton technology.  "Production of a compact proton accelerator is truly exciting and unique to the world of proton therapy and is a demonstration of our dedication to providing physicians and patients access to the highest standard of cancer care," stated Joseph Jachinowski, Still River Systems CEO. "We have built an exceptional proton therapy accelerator and are establishing a lean and solid production line with a strong organization to produce, deploy and service these accelerators worldwide."

ABOUT STILL RIVER SYSTEMS: Still River Systems, Inc., based in Littleton, Massachusetts, is dedicated to providing physicians, and their patients, access to high quality, cost-effective proton therapy solutions. Sill River Systems is developing the Monarch250, an affordable, precise and compact proton therapy systems for cancer treatment. The Monarch250 has not been cleared by the U.S. Food and Drug Administration for distribution or clinical use. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit www.stillriversystems.com


'/>"/>
SOURCE Still River Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
2. Flu Season Is Here -- Vaccinations Are Still Plentiful
3. New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need
4. K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains
5. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
6. Health Reform Bills Still Lack Strategic Focus on Health Workforce
7. New Survey Reveals Even After 12 Years of Living With Depression Adults Still Struggle Due to Lack of Basic Information
8. U.S. Department of Defense Awards $1.2 Million to Study the Use of Vigabatrin to Reduce the Addictive Liability of Opiates While Still Effectively Managing Pain
9. Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available
10. Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public
11. First Perry Baromedical Sigma Elite Hyperbaric Chamber with EMR Installed at Stillwater Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology:
(Date:4/21/2017)... Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at Palm ... , will be taking part in the 2017 London Marathon. Set to take place on ... of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, raising ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its new ... the full potential of specialty and orphan brands can only be achieved when the ... “The Unifying Effect is at the heart of a true partnership between our agency ...
(Date:4/21/2017)... ... 2017 , ... The VIA Agency , a full-service ... Theravent, Inc. , the makers of a revolutionary new device clinically proven to ... working to expand distribution in anticipation of a national launch. VIA will be ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
Breaking Medicine News(10 mins):